During the RSV season (from November 2024 to April 2025) postpartum and paediatric patients at Oak Valley Health will have the opportunity to receive nirsevimab (Beyfortus) immunization.
What is Respiratory Syncytial Virus (RSV)?
Respiratory Syncytial Virus (RSV) is a leading cause of lung infections, typically bringing on cold-like symptoms. While most people experience mild illness, RSV can lead to serious health complications in infants, young children, and older adults.
Why choose Beyfortus?
Backed by Health Canada, nirsevimab (Beyfortus) is a trusted option for families seeking RSV protection. Beyfortus is a simple injection (monoclonal antibody) that adds a layer of protection to help prevent severe RSV complications. While it is injected into the bloodstream via a jab to a muscle, nirsevimab isn’t a vaccine.
Offered at no cost to eligible families, Beyfortus provides an additional layer of defense for children at increased risk.
Who is eligible?
Beyfortus is publicly funded for RSV prevention in Ontario for:
- Infants born January 2024, up to RSV season, or during the 2024/25 RSV season.
- High-risk children up to 24 months with:
- Chronic lung disease
- Congenital heart disease
- Severe immunodeficiency
- Down syndrome (Trisomy 21)
- Cystic fibrosis
- Neuromuscular disease
- Severe congenital airway anomalies
Where to receive Beyfortus
- Markham Stouffville Hospital: Beyfortus is available to newborns born during RSV season, administered only with expressed consent, before discharge.
- Community Health Clinic (CHC) Stouffville: Starting November 1, 2024, Beyfortus is available for infants born from January 2024, up to RSV season and under 24 months of age, that meet the eligibility criteria.
- To book an appointment at CHC Stouffville, please call the clinic directly at 905-591-5454. You’ll be guided through screening questions before scheduling.